Core Insights - Shanghai Yizhong (688091) reported a revenue of 160 million yuan for the first half of 2025, representing a year-on-year growth of 31.48% [1] - The net profit attributable to shareholders reached 38.0038 million yuan, showing a year-on-year increase of 10.13% [1] - The significant revenue growth is primarily attributed to the inclusion of the core product, paclitaxel micelles, in the national medical insurance catalog, leading to a remarkable sales increase of 487% compared to the same period last year [1]

Core Viewpoint - Shanghai Yizhong Pharmaceutical Co., Ltd. reported significant growth in revenue and net profit for the first half of 2025, primarily driven by the inclusion of its core product, paclitaxel micelles, in the national medical insurance catalog, leading to a notable increase in sales volume [4][5]. Company Overview - The total assets of the company at the end of the reporting period amounted to approximately CNY 1.49 billion, reflecting a 3.19% increase compared to the end of the previous year [3]. - The net assets attributable to shareholders of the listed company also showed growth, although specific figures were not detailed [3]. Financial Performance - The company's operating revenue reached CNY 160.31 million, marking a 31.48% increase compared to the same period last year [4]. - The total profit for the period was CNY 40.17 million, which represents a 3.16% increase year-on-year [4]. - The net profit attributable to shareholders was CNY 37.06 million, up 11.74% from the previous year [4]. - The net cash flow from operating activities experienced a significant decline, amounting to a negative CNY 29.63 million, attributed to increased costs in raw material procurement, salary expenses, and R&D investments [4]. Shareholder Information - As of the end of the reporting period, the total number of shareholders was 6,521 [4]. - The top ten shareholders included individuals and corporate entities, with the largest shareholder holding 19.41% of the shares [4][5].

证券代码：688091 证券简称：上海谊众 公告编号：2025-030 上海谊众药业股份有限公司 第二届董事会第十一次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、董事会会议召开情况 上海谊众药业股份有限公司（以下简称"公司"）第二届董事会第十一次会议（以 下简称"会议"）于 2025 年 8 月 7 日以现场结合通讯方式召开，会议通知已于 2025 年 8 月 2 日以通讯方式送达全体董事。会议应出席董事 6 人，实际出席董事 6 人， 本次会议由公司董事长周劲松召集和主持。会议的召集和召开程序符合有关法律 法规的规定，会议决议合法、有效。 二、董事会会议审议情况 本次会议经全体董事表决，形成决议如下： 董事会认为：公司 2025 年半年度报告的编制和审议程序符合相关法律法规及 《公司章程》等内部规章制度的规定；公司 2025 年半年度报告的内容与格式符合 相关规定，公允地反映了公司 2025 年上半年的业绩情况与财务状况等事项；报告 的编制过程中，未发现公司参与半年报编制和审议的人员有违反保密规定的 ...

Core Viewpoint - The company plans to utilize part of its temporarily idle raised funds for cash management, ensuring that it does not affect the progress of fundraising investment projects or the company's normal operations, with a maximum amount of RMB 450 million allocated for this purpose [1][4][8] Fundraising Basic Situation - The company raised a total of RMB 1,007.745 million through the issuance of 26.45 million shares at a price of RMB 38.10 per share, with a net amount of RMB 936.030479 million after deducting issuance costs [1][2] Fundraising Usage Situation - The adjusted fundraising usage plan includes investments in the construction of facilities for the production of 5 million injection-use paclitaxel polymer micelles, clinical research for expanded indications, marketing network construction, and supplementary working capital [2][5] Cash Management Plan - The company intends to invest the idle funds in low-risk, high-liquidity products that meet capital preservation requirements, such as guaranteed financial products, structured deposits, and large certificates of deposit, with a usage period not exceeding 12 months [4][5][7] Impact on Company Operations - The cash management plan is expected to enhance the efficiency of fund usage without impacting the normal operations of the company or its fundraising investment projects, ultimately benefiting shareholders by increasing investment returns [5][6] Decision-Making Process - The board of directors approved the cash management plan on August 7, 2025, ensuring compliance with relevant regulations and safeguarding shareholder interests [6][8]

Core Points - Shanghai Yizhong Pharmaceutical Co., Ltd. reported on the status of its fundraising and actual usage for the first half of 2025, detailing the total amount raised and how it has been allocated [1][2][4] - The company raised a total of RMB 936.03 million, with a net amount of RMB 936.03 million after deducting issuance costs [1][2] - As of June 30, 2025, the remaining balance of the raised funds was RMB 424.52 million [1][2] Fundraising Overview - The company issued 26.45 million shares at a price of RMB 38.1 per share, resulting in total fundraising of RMB 1,007.75 million [1] - After deducting issuance costs of RMB 71.71 million, the net proceeds amounted to RMB 936.03 million [1] - The funds were deposited in designated accounts and managed according to regulatory requirements [1][2] Fund Management - The company established a fundraising management system to ensure the funds are used in a standardized, safe, efficient, and transparent manner [1][2] - Multiple bank accounts were opened for fund management, including accounts at Agricultural Bank of China, Bank of Communications, and China Merchants Bank [1][2] - The company has approved the temporary use of idle funds for cash management, with limits set for various periods [2][5] Actual Fund Usage - As of June 30, 2025, the company had invested RMB 580.45 million into projects, with RMB 70.77 million invested in the current period [1][4] - The company used RMB 142,358.49 for replacing self-raised funds that were used for issuance costs [1][5] - There were no instances of using excess funds for permanent working capital or repaying bank loans [2][5] Project Progress and Adjustments - The company reported delays in project timelines due to regulatory approvals and external environmental changes [4][6] - Adjustments were made to the investment amounts among different project entities to improve efficiency and ensure timely project completion [6] - The company is actively working on expanding its production capacity for the injectable paclitaxel polymer micelles [6]

Core Viewpoint - The company is committed to enhancing operational quality and core competitiveness while protecting the legitimate rights and interests of all investors, particularly small and medium-sized investors, through its "Quality Improvement, Efficiency Enhancement, and Return Focus" action plan for 2025 [1] Group 1: Business Development - The company focuses on the development of innovative anti-tumor drugs and related products, supported by a team of high-tech talents with backgrounds in polymer materials, drug formulation, and biology [1] - The company has achieved significant improvements in operational quality and efficiency, with core product marketing maintaining a steady performance [2] - The company has completed approvals for its products in over 200 key hospitals nationwide, enhancing drug accessibility and patient affordability [2] Group 2: Production Expansion - The company is implementing a project to produce 5 million injections of paclitaxel polymer micelles annually, with construction progressing smoothly and on schedule [3] - The cleanroom construction and production equipment preparations are underway, ensuring alignment with future market demand [3][4] Group 3: Clinical Research - The company is actively conducting clinical research for multiple cancer indications, with Phase II trials for ovarian, esophageal, and nasopharyngeal cancers progressing as planned [5] - Phase III trials for breast and pancreatic cancers have been initiated at over 20 research centers nationwide, with research progress meeting expectations [5] Group 4: Talent Acquisition - The company has successfully recruited 252 individuals in the first half of 2025, including 23 high-educated talents and 99 fresh graduates, enhancing its research and professional capabilities [6] Group 5: Innovation and R&D - The company is developing two new drugs: a multifunctional monoclonal antibody and a fourth-generation EGFR-TKI, both currently in preclinical research [6] - The focus for the year will be on advancing these new drugs through critical experiments to validate their efficacy and safety [6] Group 6: Investor Returns - The company emphasizes sustainable profitability and has implemented a cash dividend policy, distributing 0.3 yuan per share, totaling 43,166,400 yuan, which is 30.22% of the net profit attributable to shareholders [7][8] - The company has repurchased 1,274,307 shares, amounting to 37,240,964.92 yuan, reinforcing its commitment to maintaining long-term investment value [8] Group 7: Investor Communication - The company has enhanced its investor communication by expanding channels and improving the quality of information disclosure, thereby increasing investor confidence [9] - Regular training for key personnel has been conducted to ensure accurate and timely information disclosure, reflecting the company's investment value [9] Group 8: Corporate Governance - The company is continuously improving its governance structure and internal control systems to ensure stable operations and enhance financial management [10] - The company has revised key governance documents to clarify the responsibilities of its management team, aligning their performance with shareholder interests [10] Group 9: Future Outlook - The company will continue to focus on its main business development and maintain a stable and resilient long-term profitability, ensuring the protection of all shareholders' rights [11]

Core Viewpoint - Shanghai Yizhong (SH 688091, closing price: 76.37 yuan) announced on August 7 that its 11th meeting of the second board of directors was held, where the implementation assessment report of the "Quality Improvement, Efficiency Enhancement, and Return to Shareholders" action plan for 2025 was reviewed [2]. Financial Performance - For the year 2024, Shanghai Yizhong's revenue composition was as follows: chemical pharmaceuticals accounted for 99.71%, while other businesses made up 0.29% [2].

Core Insights - Shanghai Yizhong (SH 688091) reported a revenue of approximately 160 million yuan for the first half of 2025, representing a year-on-year increase of 31.48% [2] - The net profit attributable to shareholders was around 38 million yuan, reflecting a year-on-year growth of 10.13% [2] - Basic earnings per share reached 0.18 yuan, which is a year-on-year increase of 5.88% [2]

上海谊众致力于抗肿瘤创新药及相关产品的开发，拥有高分子材料、药物制剂、 生物学等背景的高科技人才，具备独立自主的药品研发能力与完整的药品生产系 统，是一家集研发、生产、销售为一体的高科技制药企业。 2025 年上半年，公司严格贯彻"提质增效重回报"行动方案，持续强化风险 管控，筑牢"安全、稳健"发展根基，为高效率、高质量的综合发展提供了坚实保 障。凭借在研发、生产、营销及产品价值创造等领域的核心竞争优势，公司坚定聚 焦主业发展，核心产品营销保持稳健态势。同时，公司高效推进募投项目建设与创 新药研发等关键经营工作，在重点领域取得显著提质增效成果，整体经营质量与效 率获得实质性提升，高质量发展迈出坚实步伐。 （一） 传递产品价值，夯实市场竞争基础 上海谊众药业股份有限公司关于 2025 年度"提质增效重回报"行动方案的 半年度评估报告 为深入贯彻"以投资者为本"的核心理念，持续提升经营发展质量与核心竞争 力，切实维护投资价值并保护全体投资者（特别是中小投资者）的合法权益，上海 谊众药业股份有限公司（以下简称"公司"）于 2025 年 6 月 7 日披露了《2025 年 度"提质增效重回报"行动方案》（以下简称"方 ...

上海谊众药业股份有限公司 募集资金存放与实际使用情况专项报告 上海谊众药业股份有限公司 2025 年半年度 募集资金存放与实际使用情况的专项报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重 大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 根据《上市公司募集资金监管规则》和上海证券交易所《上海证券交易所科创板 上市公司自律监管指引第 1 号——规范运作》的规定，上海谊众药业股份有限公司 （以下简称本公司或公司）对 2025 年 1-6 月募集资金存放与使用情况报告如下： 一、募集资金基本情况 经中国证券监督管理委员会证监发行字[2021]2595 号文核准，本公司向社会公开 发行人民币普通股（A 股）2,645 万股，每股发行价为 38.1 元，应募集资金总额为人民 币 100,774.50 万元，根据有关规定扣除发行费用 7,171.45 万元后，实际募集资金净额 为 93,603.05 万元。该募集资金已于 2021 年 9 月 3 日到账，到账情况业经容诚会计师 事务所容诚验字【2021】201Z0041 号《验资报告》验证。 公司对募集资金采取了专户存储管理。 ...